Second-line XXXX plus @entity900 for advanced @entity356 showing resistance to S-1.

@entity1 @entity137 @entity900 @entity1431 @entity1205 @entity356
The purpose of this study was to clarify the efficacy and safety of @entity1205 and @entity900 as second-line treatment for @entity1 with S-1 refractory advanced @entity356 . Between 1999 and 2006, 32 @entity1 received @entity1205 (60 mg/m  ) and @entity900 (60 mg/m  ) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable @entity137 was detected. The overall response rate was 21.9%. Seven @entity1 showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were @entity1431 and neutropnea. Non-hematological @entity137 were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for @entity1 with @entity356 refractory to S- 1 chemotherapy.
